FDA approved Plozasiran (now REDEMPLO™) on November 18, 2025, for reducing triglycerides in adults with FCS, the first siRNA therapy for this rare disease. ARWR boasts a diversified RNAi pipeline ...

With a fresh FDA endorsement for its drug plozasiran, California-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm. Complicating the matter, however, is the fact ...

Manners and Masquerade - A Regency Romance set on the Isle of Wight will be performed at Niton Village Hall from December 5 ...

NORTH HOLMES WELL. IT IS THE HOME OF THE CHIEFS FOR NOW, AS THE TEAM CONSIDERS RENOVATING ARROWHEAD STADIUM OR MOVING AWAY FROM THE TRUMAN SPORTS COMPLEX. BUT IF THE CHIEFS STAY, ARROWHEAD COULD GET A ...

The Chiefs continue to move toward an inevitable decision between renovating Arrowhead Stadium and building a new stadium. On Monday, Chiefs owner Clark Hunt addressed the status of the team’s effort ...

"In Texas, you may dig and collect American Indian artifacts, such as arrowheads, on your own property or someone else's with their permission," the post read. "You cannot legally dig in or disturb ...

Among the quiet pines above Lake Arrowhead, a battle is underway, one that will decide who calls the shots in the unincorporated community nestled in the San Bernardino Mountains. In 1915, property ...

Pasadena-based Arrowhead Pharmaceuticals Inc. has announced another major licensing deal with a pharma giant. This one is with Basel, Switzerland-based Novartis for $200 million in upfront payment and ...

Firelands Archeology hosted for the first time Flintbusters and Beyond for community members to learn more about flint and its uses through time. The free program, hosted at French Creek Nature Center ...

Sept 11 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab sued biotech rival Arrowhead Pharmaceuticals (ARWR.O), opens new tab for patent infringement in California federal court on Thursday ...

Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent. Arrowhead claims ...

The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology. For reference, the TRiM platform is a key part of the investment case for the stock. Arrowhead's ...